Uncategorized
Annexon Shares Soar as ANX005 Meets Primary Endpoint in Phase 3 Trial for Guillain-Barré Syndrome
Annexon, ANX005, Guillain-Barré Syndrome, Phase 3 Trial, Primary Endpoint, Disability Reduction, Share Price Surge
Miniature Swine: Revolutionizing Nonclinical Studies for Small Molecules and Biologics
Miniature swine, Nonclinical studies, Small molecules, Biologics, Dermal testing, Safety assessments, Research models
Akeso and Summit’s Keytruda-Topping Results in NSCLC Generate Significant Interest at ASCO
Akeso, Summit, Keytruda, NSCLC, ASCO, Merck, Ivonescimab, PD-1, VEGF, Cancer Treatment
Brandon Capital Raises $180M Fund to Boost Australia and New Zealand Biotechs
Brandon Capital, biotechs, Australia, New Zealand, life sciences, venture capital, fund, startups, scale-ups
Illumina’s Board Approves Spin-Off of Grail, a Cancer Diagnostics Firm
Illumina, Grail, spin-off, cancer diagnostics, DNA sequencing
Structure Therapeutics’ Oral GLP-1 Achieves Comparable Weight Loss to Lilly’s Candidate
Structure Therapeutics, GLP-1, Obesity, Weight Loss, Lilly, Oral Candidate
Biotech Faces a Reckoning: The Challenges and Shifts in Cell Therapies
cell therapy, biotech, gene therapy, autoimmune diseases, manufacturing challenges, market acceptance, pharmaceutical industry
LGBTQ+ Populations Face Higher Cancer Risk Due to Barriers to Healthcare
LGBTQ+, cancer risk, barriers to healthcare, American Cancer Society, discrimination, minority stress
Takeda’s Orexin Narcolepsy Drug TAK-861 Poised for Phase III Trials After Promising Results
Takeda, TAK-861, narcolepsy, orexin receptor 2 agonist, Phase III trials, narcolepsy type 1, sleep disorders
Intellia Therapeutics Reports Promising Long-Term Data for Single-Dose HAE Therapy
Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), CRISPR Gene Editing, Single-Dose Treatment, Long-Term Data